The case for open‐access chemical biology
Open Access
- 21 August 2009
- journal article
- Published by Springer Nature in EMBO Reports
- Vol. 10 (9), 941-945
- https://doi.org/10.1038/embor.2009.193
Abstract
No abstract availableThis publication has 24 references indexed in Scilit:
- FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell LymphomaThe Oncologist, 2007
- The scientific impact of the Structural Genomics Consortium: a protein family and ligand-centered approach to medically-relevant human proteinsJournal of Structural and Functional Genomics, 2007
- MMPs as therapeutic targets—Still a viable option?Seminars in Cell & Developmental Biology, 2007
- Governmental influences on drug development: striking a better balanceNature Reviews Drug Discovery, 2007
- Crystal structures of histone demethylase JMJD2A reveal basis for substrate specificityNature, 2007
- DecitabineNature Reviews Drug Discovery, 2006
- Drug discovery in jeopardyJournal of Clinical Investigation, 2006
- Article Commentary: Fundamental Problems Lie Ahead in the Drug Discovery and Commercialization Process: Restructuring of the Pharmaceutical Industry and an Improved Partnership with Academia are RequiredJournal of Investigative Medicine, 2006
- Crystal structure of the CorA Mg2+ transporterNature, 2006
- How many genomics targets can a portfolio afford?Drug Discovery Today, 2005